When was Exin Therapeutics founded?

Exin Therapeutics was founded in 2024 and raised its 1st funding round 1 year after it was founded.

Where is Exin Therapeutics located?

Exin Therapeutics is headquartered in San Francisco, United States.

Who is the current CEO of Exin Therapeutics?

Gabriel Ocana Santero of Exin Therapeutics. They have also founded 1 company.

Is Exin Therapeutics a funded company?

Exin Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on 2025.

When was the latest funding round of Exin Therapeutics?

Exin Therapeutics' latest funding was a $***** Seed round on 2025, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $1.02B in funding in 2026 to date.

Where does Exin Therapeutics rank among its competitors?

Exin Therapeutics ranks 285th amongst 448 active competitors, of which 153 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Mission Therapeutics, which secured $13.3M in Oct, 2025.

Who are the top competitors of Exin Therapeutics?

Exin Therapeutics' top competitors include Alector, Juvenescence and Annexon. Among them, Mission Therapeutics secured the most recent funding round in October, 2025.

Exin Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Exin Therapeutics is a seed company based in San Francisco (United States), founded in 2024 by Gabriel Ocana Santero. It operates as a Developer of precision genetic therapies targeting dysregulated neural circuits across various disorders. Exin Therapeutics has raised $500K in funding. The company has 448 active competitors, including 153 funded and 82 that have exited. Its top competitors include companies like Alector, Juvenescence and Annexon.

Company Details

Developer of precision genetic therapies targeting dysregulated neural circuits across various disorders. The therapies aim to restore normal neural activity and address neurological conditions such as autism spectrum disorder, epilepsy, and Parkinson’s disease.

Key Metrics

Founded Year

2024

Location

San Francisco, United States

Stage

Seed

Total Funding

$500K in 1 round

Latest Funding Round

Seed, 2025, $*****

Investors

Y Combinator & 1 more

Ranked

285^th among 448 active competitors

Similar Companies

Alector & 558 more

View Exin Therapeutics' full profile

Exin Therapeutics has raised a total funding of $500K over 1 round. Its latest funding round was a Seed round on 2025 for $*****. 1 investor participated in its latest round. Exin Therapeutics has 2 institutional investors.

Here is the list of recent funding rounds of Exin Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
2025	4487	Seed	6790	8714	4262	7483

Access funding benchmarks and valuations. Sign up today!

View details of Exin Therapeutics's funding rounds and investors

The founders of Exin Therapeutics is Gabriel Ocana Santero. Gabriel Ocana Santero is the CEO of Exin Therapeutics.

Here are the details of Exin Therapeutics' key team members:

Gabriel Ocana Santero: Co-Founder and CEO of Exin Therapeutics.
Contact Info: 1 email address

View details of Exin Therapeutics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Exin Therapeutics include Alector, Juvenescence and Annexon. Here is the list of Top 10 competitors of Exin Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	72/100
2nd	Juvenescence 2017, Dublin (Ireland), Series B	Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health	$290M	Ipgl, Foresite Capital & 9 others	68/100
3rd	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, New Enterprise Associates ... & 16 others	67/100
4th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Orbimed, Perceptive Advisors & 5 others	65/100
5th	AviadoBio 2019, London (United Kingdom), Series A	Developer of gene therapies for neurodegenerative disorders	$80M	New Enterprise Associates, Monograph & 9 others	65/100
6th	Axsome Therapeutics 2012, New York City (United States), Public	Developer of therapeutic solutions for the management of CNS disorders	$8.7M	SVB Securities, Collage Venture Partners	65/100
7th	US World Meds 2001, Louisville (United States), Series B	Developer of therapeutics for the treatment of multiple diseases	$149M	Athyrium Capital Management, CRG & 5 others	63/100
8th	Cognition Therapeutics 2007, Pittsburgh (United States), Public	Developer of small molecule drugs for neurodegenerative diseases	$36.1M	Golden Seeds, iNetworks & 28 others	63/100
9th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Small molecule drugs that target deubiquitylating enzymes involved in the DNA damage response	$192M	Pfizer Venture Investments, Sofinnova Partners ... & 46 others	62/100
10th	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, Leaps by Bayer & 1 others	62/100
285th	Exin Therapeutics 2024, San Francisco (United States), Seed	Developer of precision genetic therapies targeting dysregulated neural circuits across various disorders	$500K	Y Combinator, Ajira	28/100